Damora Therapeutics, Inc. 8-K

What Happened
Damora Therapeutics, Inc. (DMRA) filed an 8-K reporting the results of its Annual Meeting of Stockholders held June 17, 2026. There were 60,303,212 shares outstanding as of the April 22, 2026 record date and 55,009,938 shares were represented at the meeting (quorum). The company elected both Class III director nominees, received an advisory approval for executive compensation (Say-on-Pay), chose a one‑year frequency for future advisory votes on compensation, and ratified Ernst & Young LLP as its independent auditor for fiscal 2026.

Key Details

• Election of Directors: Michael Landsittel — For 51,403,541; Withheld 29,011; Broker non-votes 3,577,386. Cameron Turtle, D.Phil — For 51,403,540; Withheld 29,012; Broker non-votes 3,577,386. Both elected to serve through the 2029 annual meeting.
• Say-on-Pay (advisory): For 51,401,988; Against 3,546; Abstain 27,018; Broker non-votes 3,577,386. The advisory compensation vote was approved.
• Say-on-Frequency (advisory): 1 Year 50,913,167; 2 Years 103; 3 Years 518,015; Abstain 1,267. The plurality favored annual votes; the Board will hold say-on-pay votes every year.
• Ratification of Auditor: Ernst & Young LLP ratified — For 54,977,317; Against 5,640; Abstain 26,981.

Why It Matters
These votes confirm the company’s board composition and give shareholders an advisory approval of executive pay and auditor selection—routine governance matters investors watch for indications of board accountability and oversight. The Board’s decision to hold annual say-on-pay votes reflects shareholder preference for yearly advisory input on executive compensation.